作为一种潜在的免疫治疗点,MAL与癌症患者的预后不佳有关
Ruinian Zheng1, Biao Yao2, Yongkang Ye3
1Department of Oncology, Dongguan Institute of Clinical Cancer Research, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People's Hospital), Dongguan, Guangdong 523059, China. 2857311978@qq.com.
髓和淋巴细胞 (MAL) 蛋白质,主要在T细胞中,影响癌症免疫力. 低MAL水平与生存率差相关,这表明MAL是各种癌症的潜在免疫治疗标.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
背景情况:
- 马尔基因编码了髓和淋巴细胞蛋白,这对T细胞功能和免疫调节至关重要.
- 它在调节免疫透和在胰腺癌的预后意义上的精确作用尚不清楚.
研究的目的:
- 在泛癌背景下研究MAL的表达,预后价值和免疫调节机制.
- 评估MAL作为癌症免疫治疗的潜在目标.
主要方法:
- 使用TCGA,TIMER2.0,GTEx,UCSC和TISCH数据库进行全面分析.
- 雇佣R编程用于统计分析和数据解释.
主要成果:
- 与健康对照人群相比,MAL在大多数恶性瘤中表现出差异性表达.
- 较低的MAL表达与乳腺侵入性癌 (BRCA) 和肺腺癌 (LUAD) 队列的不良生存率有关.
- 马尔与T细胞和B细胞的丰富性有显著的相关性,并与BRCA和LUAD的关键免疫路径有关.
结论:
- 马尔显示出显著的预后价值,并在癌症免疫调节中发挥作用.
- 在多种癌症类型中,MAL是开发新型免疫治疗策略的有希望的目标.
更多相关视频
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
07:44Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
相关概念视频
Tumor Immunotherapy
The Tumor Microenvironment
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
